PGY-3 at @MGBpathology @harvardmed 🔬| Dermatopathology fellow 2028-2029 @BIDMCpath @harvardmed @DanaFarber @BostonChildrens | Globetrotter 🌎🇦🇷✈️
Joined January 2023
- Tweets160
- Following323
- Followers467
- Likes2K
Pinned Tweet
THIS IS SURREAL!!!!
I matched to Mass General Brigham Pathology!!! Can’t wait to start this amazing adventure with this great group of people!!! 🥹😄🥳🍾
@BWHPath @MGHPathology
#Match2024 #PathTwitter #path2path
Federico Repetto, MD retweeted
Happy to share our latest publication in Virchows Archiv!
We report a rare OGT-rearranged mesenchymal neoplasm of the palm harboring a novel OGT::C3orf62/MAPS fusion, expanding the molecular spectrum of this emerging entity.
#Dermpath #Pathology
doi.org/10.1007/s00428-026-0…
Excited to share our new paper in Virchow Archiv! 🔬
We report an OGT-rearranged mesenchymal neoplasm of the palm with a novel OGT::C3orf62/MAPS fusion, expanding the molecular spectrum of this rare tumor.
A fun case with some interesting diagnostic and molecular twists 👇
Thanks so much, @JLHornick, for this beautiful gift! A must-read for anyone interested in dermpath and surgical pathology. Excited to dive in! 📚🔬 – at Boston, MA
Excited to share our case published in @BloodPortfolio! 🩸
We highlight an unusual intramuscular relapse of BPDCN without active skin disease and stepwise TP53 progression superimposed on canonical TET2 founder alterations.
🔗 ashpublications.org/blood/ar…
Great to see our work highlighted! 🙌
In our @JAMADerm study, EV–associated skin toxicities (particularly those occurring early in treatment) were associated with improved survival in patients with advanced urothelial carcinoma.
Excited to see where these findings lead! 🔬
Early EV rash may be associated with response
📈 EV-attributed skin toxicity: OS HR 0.46, PFS HR 0.60 at the 30-day landmark
🎯 Onset by day 15 carried the signal. Late rash did not.
⚠️ High-grade rash did not predict worse survival
Retrospective, and the rash group started healthier, ECOG 0 in 57% vs 33%.
Hope we continue to learn more as we understand dose intensity and response how we can best manage what can be severe skin toxicity. Topical and oral steroids, dose hold, and dose reductions.
👉 bit.ly/lee-ev-rash-2026
#BladderCancer #UrothelialCA #GUonc #ADC
Federico Repetto, MD retweeted
Early EV rash may be associated with response
📈 EV-attributed skin toxicity: OS HR 0.46, PFS HR 0.60 at the 30-day landmark
🎯 Onset by day 15 carried the signal. Late rash did not.
⚠️ High-grade rash did not predict worse survival
Retrospective, and the rash group started healthier, ECOG 0 in 57% vs 33%.
Hope we continue to learn more as we understand dose intensity and response how we can best manage what can be severe skin toxicity. Topical and oral steroids, dose hold, and dose reductions.
👉 bit.ly/lee-ev-rash-2026
#BladderCancer #UrothelialCA #GUonc #ADC
Excited to share our latest publication! We describe the first dedicated case series of undiff/dediff melanoma involving the GU tract, highlighting an important diagnostic pitfall.
journals.sagepub.com/doi/10.….
#PathTwitter #Dermpath #GUPath 🔬🧬
@MichelleDunno17 @MGBpathology
I couldn’t be happier to share that I have accepted a position as a Dermatopathology Fellow at @BIDMCpath/@harvardmed. I’m incredibly grateful and excited for this next chapter in my training. 😁🙌
BIDMC already has an exceptionally experienced dermpath group, and it is entering an exciting period of growth with the addition of world-renowned faculty, including my mentor Dr. George Murphy and Dr. Adriano Piris, part of Dr. Martin Mihm’s unremarkable legacy.
2
10
647
With the addition of @DanaFarber, one of the nation’s leading cancer centers, and the opportunity to rotate through @BostonChildrens, I could not be more excited for the future and for the training ahead. Extremely grateful to my mentors for making this possible! 😊
9
442
Federico Repetto, MD retweeted
Introducing our new MGB Pathology PGY-1s!! We’re so excited for you to join us and can’t wait to welcome you to the path family 🎉🔬🧫🤍
Honored to receive the @ASDPTweets 2026–2027 Mentorship Award! 🥳 Thank you to ASDP and everyone who supported this application. Looking forward to my 2 week rotation at @MSKPathology with Dr. @KonstantinosLin 🎖️
#Dermpath #PathTwitter
Federico Repetto, MD retweeted
Cutaneous plasmablastic lymphoma is a rare, aggressive tumour. In the largest published series to date, the authors compare primary with secondary lesions, outline the clinical and histological features, and explore the relationships with EBV status. onlinelibrary.wiley.com/shar…
Happy to share our recently published paper on enfortumab vedotin, a new frontline player in bladder cancer, and the skin reactions it can cause (plus practical path clues to recognize it!). 🔬💉
@RosNazarianMD @MGBpathology
#PathTwitter #Dermpath
🔗 onlinelibrary.wiley.com/doi/…
Excited to share our recently published paper on cutaneous plasmablastic lymphoma 🔬
Thanks so much to my mentors! @RosNazarianMD @judith_ferry @KMCornejoMD 🙌
🔗 onlinelibrary.wiley.com/doi/…
#Dermpath #Hemepath
@Histo_Journal @MGBpathology
I’m so happy to share our new manuscript, now published in @LIjournal, where we highlight key mechanisms of cutaneous alloreactivity and discuss how these insights inform transplantation, immune-mediated skin disease, and modern immunotherapies. 🔬🧬
#PathTwitter #DermPath
Federico Repetto, MD retweeted
Day 5 of our MGB pathology course!
Great talk today by Dr. Sholl on molecular features and treatment options for thoracic tumors!
Federico Repetto, MD retweeted
🍫Mentorship in dermatopathology is as rewarding as it is reciprocal. Deeply grateful to my trainees - past, present and future - for the curiosity, kindness and inspiration you bring.
#Dermpath #dermtwitter #Mentorship #sponsor #grateful @RepettoF_MD @MGBpathology @harvardmed
